Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 4
2005 6
2006 2
2007 4
2008 3
2009 3
2010 2
2013 3
2015 1
2018 1
2021 1
2022 1
2023 4
2024 3
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial.
Geetha D, Pagnoux C, Sattui SE, Merkel PA, Weiner M, Draibe J, Faguer S, Bray S, Gurlin RE, Balcells-Oliver M, Bruchfeld A, Jayne DR; ADVOCATE Study Group. Geetha D, et al. Rheumatology (Oxford). 2025 Jun 1;64(6):3863-3871. doi: 10.1093/rheumatology/keaf122. Rheumatology (Oxford). 2025. PMID: 40037556 Free PMC article. Clinical Trial.
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial.
Walsh M, Collister D, Gallagher M, Mark PB, de Zoysa JR, Tyrwhitt J, Tennankore K, Reis G, Xavier D, Liu WJ, Zuo L, Wang AY, Félix C, Sola L, Arici M, Villanueva R, Jha V, Précoma D, Rabbat CG, Alavudeen SS, Faruqui AR, López-Flecher M, Pyne L, Wald R, Yuan F, Balasubramanian K, Lee SF, Kuptsova A, Christou C, Devereaux PJ; ACHIEVE Investigators. Walsh M, et al. Lancet. 2025 Aug 16;406(10504):695-704. doi: 10.1016/S0140-6736(25)01198-5. Lancet. 2025. PMID: 40818850 Clinical Trial.
Treatment With Avacopan in ANCA-Associated Vasculitis With Kidney Involvement.
Geetha D, Cortazar FB, Bruchfeld A, Kronbichler A, Karras A, Nakhoul GN, Merkel PA, Bray S, Bozeman AM, Jayne DRW; ADVOCATE Study Group. Geetha D, et al. Kidney Int Rep. 2025 Jun 2;10(8):2751-2765. doi: 10.1016/j.ekir.2025.05.041. eCollection 2025 Aug. Kidney Int Rep. 2025. PMID: 40814647 Free PMC article.
Heparanase in glomerular diseases.
van den Hoven MJ, Rops AL, Vlodavsky I, Levidiotis V, Berden JH, van der Vlag J. van den Hoven MJ, et al. Among authors: levidiotis v. Kidney Int. 2007 Sep;72(5):543-8. doi: 10.1038/sj.ki.5002337. Epub 2007 May 23. Kidney Int. 2007. PMID: 17519955 Free article. Review.
40 results